Leanna Levine,
Founder & CEO,
ALine, Inc.
Dr. Levine, founder of ALine, Inc., is an entrepreneur, technologist, and inventor. She has a unique blend of technical expertise in both bioanalytical science and manufacturing process development. Prior to founding ALine, Dr. Levine developed bioanalytical technology to support life science research. While at Monsanto, her lab led the industry in the application of fluorescence polarization for high throughput screening for novel therapeutics. In 1998 she joined Spectrum Laboratories as Director of Hollow Fiber Manufacture and Product Development. Dr. Levine earned her Ph.D. at Washington University, St. Louis, MO , and her B.S. in Biochemistry and BA in German from the University of Missouri, Columbia, MO. In 2003 she was a visiting scholar at the UCLA Anderson School of Business. In 2000 she was the chair of the Gordon Conference on Bioanalytical Sensors. She is the co-author on a dozen publications, and several patents.
|
|
Why Considering the Impact of Cartridge Architecture Matters for the Final Product Cost of GoodsTuesday, 8 October 2019 at 15:30  Add to Calendar ▼2019-10-07 00:00:002019-10-07 01:00:00Europe/LondonTitle to be Confirmed.SELECTBIOenquiries@selectbiosciences.comAs microfluidics-based products mature and move toward the consumer market, the drive toward a lower cost of goods for the instrument, in addition to a low-cost consumable, requires consideration of the overall cartridge architecture and the instrument interface early in the development program. For example, choices in the valve design and actuation method can lead to the instrument, rather than the assay protocol, driving the cartridge design. In this presentation, we will review examples and strategies that have been implemented in development programs, and provide context on the impact of different choices on the system, including impact on the size of the microfluidics-based consumable, and overall system complexity.
|
